^
Association details:
| Biomarker: | ALK fusion |
|---|---|
| Cancer: | Glioma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma
Published date:
08/19/2021
Excerpt:
A child near death with an ALK-fusion–positive high-grade glioma refractory to standard treatment had a dramatic response when treatment with lorlatinib was begun. The drug was stopped once the child had an apparent complete remission, but treatment with lorlatinib resumed when relapse occurred 6 months later.
DOI:
10.1056/NEJMc2101264
